Radiologic and Pathologic Response Evaluation After Neoadjuvant Chemotherapy for Primary Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Collaboration
Stijn J. C. van der Burg(The Netherlands Cancer Institute), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Kenneth Cardona(Emory University), Ferdinando Cananzi(Humanitas University), John E. Mullinax(Moffitt Cancer Center), Valerie P. Grignol(Ohio State University Hospital), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), Marco Fiore(Institute of Cell Biology and Neurobiology), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Winan J. van Houdt(Diakonessenhuis hospital), Markus Albertsmeier(LMU Klinikum), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Elisabetta Pennacchioli(European Institute of Oncology), Jacek Skoczylas(The Maria Sklodowska-Curie National Research Institute of Oncology), David Gyorki(The University of Melbourne), Lars H. Lindner(Ludwig-Maximilians-Universität München)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k